Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Partridge

Showing results (271-280 of 336) with videos related to

Pageof 34
Sort By:
The AAPS Journal|July 13, 2022
Comparison of Titer and Signal to Noise (S/N) for Determination of Anti-drug Antibody Magnitude Using Clinical Data from an Industry ConsortiumMarta Starcevic Manning, Mohamed Hassanein, Michael A Partridge, et al.
The AAPS Journal|June 21, 2022
Interference in a Neutralizing Antibody Assay for Odronextamab, a CD20xCD3 Bispecific mAb, from Prior Rituximab Therapy and Possible Mitigation StrategySusan C Irvin, Amanda D'Orvilliers, Nicolin Bloch, et al.
Human Molecular Genetics|January 24, 2014
Human skeletal muscle xenograft as a new preclinical model for muscle disordersYuanfan Zhang, Oliver D King, Fedik Rahimov, et al.
Cancer Research|September 18, 2004
alpha2HS-glycoprotein, an antagonist of transforming growth factor beta in vivo, inhibits intestinal tumor progressionCarol J Swallow, Emily A Partridge, Jennifer C Macmillan, et al.
Physical Chemistry Chemical Physics : PCCP|October 17, 2018
Direct solid state NMR observation of the <sup>105</sup>Pd nucleus in inorganic compounds and palladium metal systemsThomas J N Hooper, Thomas A Partridge, Gregory J Rees, et al.
JCI Insight|March 28, 2020
TGF-β-driven muscle degeneration and failed regeneration underlie disease onset in a DMD mouse modelDavi Ag Mázala, James S Novak, Marshall W Hogarth, et al.
The AAPS Journal|October 5, 2021
Bioanalytical Challenges due to Prior Checkpoint Inhibitor Exposure: Interference and Mitigation in Drug Concentration and Immunogenicity AssaysAndrew F Dengler, Rachel Weiss, Tiffany Truong, et al.
Molecular Cancer Therapeutics|April 14, 2005
Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitorDavid McKillop, Elizabeth A Partridge, John V Kemp, et al.
The Journal of Cell Biology|May 16, 2002
Myogenic cell proliferation and generation of a reversible tumorigenic phenotype are triggered by preirradiation of the recipient siteJennifer E Morgan, Jacqueline G Gross, Charles N Pagel, et al.
Journal of Neuromuscular Diseases|September 27, 2021
Interrogation of Dystrophin and Dystroglycan Complex Protein Turnover After Exon Skipping TherapyJames S Novak, Rita Spathis, Utkarsh J Dang, et al.
Pageof 34

Showing results (271-280 of 336) with videos related to

Sort By:
Pageof 34
The AAPS Journal|July 13, 2022
Comparison of Titer and Signal to Noise (S/N) for Determination of Anti-drug Antibody Magnitude Using Clinical Data from an Industry ConsortiumMarta Starcevic Manning, Mohamed Hassanein, Michael A Partridge, et al.
The AAPS Journal|June 21, 2022
Interference in a Neutralizing Antibody Assay for Odronextamab, a CD20xCD3 Bispecific mAb, from Prior Rituximab Therapy and Possible Mitigation StrategySusan C Irvin, Amanda D'Orvilliers, Nicolin Bloch, et al.
Human Molecular Genetics|January 24, 2014
Human skeletal muscle xenograft as a new preclinical model for muscle disordersYuanfan Zhang, Oliver D King, Fedik Rahimov, et al.
Cancer Research|September 18, 2004
alpha2HS-glycoprotein, an antagonist of transforming growth factor beta in vivo, inhibits intestinal tumor progressionCarol J Swallow, Emily A Partridge, Jennifer C Macmillan, et al.
Physical Chemistry Chemical Physics : PCCP|October 17, 2018
Direct solid state NMR observation of the <sup>105</sup>Pd nucleus in inorganic compounds and palladium metal systemsThomas J N Hooper, Thomas A Partridge, Gregory J Rees, et al.
JCI Insight|March 28, 2020
TGF-β-driven muscle degeneration and failed regeneration underlie disease onset in a DMD mouse modelDavi Ag Mázala, James S Novak, Marshall W Hogarth, et al.
The AAPS Journal|October 5, 2021
Bioanalytical Challenges due to Prior Checkpoint Inhibitor Exposure: Interference and Mitigation in Drug Concentration and Immunogenicity AssaysAndrew F Dengler, Rachel Weiss, Tiffany Truong, et al.
Molecular Cancer Therapeutics|April 14, 2005
Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitorDavid McKillop, Elizabeth A Partridge, John V Kemp, et al.
The Journal of Cell Biology|May 16, 2002
Myogenic cell proliferation and generation of a reversible tumorigenic phenotype are triggered by preirradiation of the recipient siteJennifer E Morgan, Jacqueline G Gross, Charles N Pagel, et al.
Journal of Neuromuscular Diseases|September 27, 2021
Interrogation of Dystrophin and Dystroglycan Complex Protein Turnover After Exon Skipping TherapyJames S Novak, Rita Spathis, Utkarsh J Dang, et al.
Pageof 34